Siemens Healthineers (SHL) Stock Price, Fundamentals & Analysis

What SHL does

Siemens Healthineers (SHL) is a medical devices company that develops, manufactures, and sells diagnostic and therapeutic products and services to healthcare providers worldwide. It operates through four segments: Imaging (MRI, CT, X-ray, molecular imaging, and ultrasound systems), Diagnostics (in-vitro diagnostic products and laboratory workflow solutions), Varian (cancer care technologies such as microwave, cryoablation, and embolization), and Advanced Therapies. The company is headquartered in Forchheim, Germany, and employs 74,300 people. Siemens Healthineers is listed on Xetra, and it is part of the DAX.

Key numbers explained

• 37.79 EUR is the latest price per share on the Xetra exchange.
• The trailing P/E ratio of 19.2 shows how much investors pay for each euro of the company's last twelve months of earnings; a lower P/E ratio can suggest a cheaper valuation relative to earnings.
• The forward P/E ratio of 16.1 uses expected future earnings and is often read as a more forward-looking valuation measure.
• The dividend yield of 2.65% tells you the annual dividend as a percentage of the share price; it is a common way to compare income across stocks.
• The ex-dividend date is Feb 6, 2026; buyers on or after this date do not receive the upcoming dividend.
• 51% of earnings are paid out as dividends, which indicates the share of profit returned to shareholders.
• Beta of 0.84 suggests the stock tends to move less than the overall market.
• The 52-week range of 32.81 – 49.71 EUR shows the lowest and highest traded prices over the past year.

What to watch

• Revenue growth of 1.8% year over year and a profit margin of 9.6% show how sales translate into bottom-line profit.
• The operating margin of 16.4% and return on equity of 12.1% are common measures of how efficiently the company uses its resources.
• A debt-to-equity ratio of 78.3% indicates the level of debt relative to shareholders' equity.
• The price-to-book ratio of 2.21 compares the market price to the company's book value per share.
• The next earnings report is scheduled for Nov 5, 2026, which is a typical catalyst for price movement.
• Investors tracking medical devices may also follow peers such as Fresenius Medical Care (FME), Fresenius (FRE), Merck (MRK), Bayer (BAYN), and Qiagen (QIA).